Chengda Pharmaceutical Co., Ltd
Initial public offering and listing on GEM
Announcement on online subscription and winning rate
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
The application of Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as “Chengda pharmaceutical” or “the issuer”) for initial public offering of no more than 24174035 ordinary shares (A shares) (hereinafter referred to as “this offering”) has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”), It has been approved for registration by China Securities Regulatory Commission (zjxk [2021] No. 3857).
The issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement (hereinafter referred to as “offline issuance”) to qualified offline investors and online pricing issuance (hereinafter referred to as “online issuance”) to social public investors holding non restricted A-share shares and market value of non restricted depositary receipts in Shenzhen market.
The issuer and the sponsor (lead underwriter) Everbright Securities Company Limited(601788) (hereinafter referred to as the “sponsor (lead underwriter)”) negotiated and determined that the number of shares issued this time is 24174035 shares, and the issue price is 72.69 yuan / share, It shall not exceed the median and weighted average of offline investors\’ quotations after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation The enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower.
According to the issuing price, the relevant subsidiaries of the sponsor do not participate in the strategic placement. Only the senior management and core employees of the issuer participate in the special asset management plan established by the strategic placement. The final number of strategic placement is 907965 shares, accounting for about 3.76% of the total number of this issuance, The difference between the initial strategic placement and the final strategic placement was 2718140 shares, which were transferred back to offline issuance.
After the strategic placement callback and before the online and offline callback mechanism was launched, the number of offline issuance was 17102070 shares, accounting for 73.51% of the number issued after deducting the final strategic placement; The number of shares issued online was 61640000, accounting for 26.49% of the number issued after deducting the final strategic placement. The total number of final offline and online issuance is the total number of this issuance minus the final strategic placement, with a total of 23266070 shares. The final number of online and offline issuance will be determined according to the callback.
The issuer initially issued 6164000 shares of “Chengda pharmaceutical” by using the online pricing of the trading system of Shenzhen Stock Exchange on January 10 (T) 2022.
Investors are kindly requested to pay attention to the payment link of this offering and timely fulfill their payment obligations on January 12, 2022 (T + 2):
1. Offline investors shall, according to the announcement on the initial public offering of shares by Chengda Pharmaceutical Co., Ltd. and the preliminary placement results of offline issuance listed on the gem, timely and fully pay the subscription funds for new shares according to the finally determined issuance price and allocated quantity before 16:00 on January 12 (T + 2) 2022.
The subscription funds shall be paid in full within the specified time. If the subscription funds are not paid in full within the specified time or as required, all the new shares allocated to the placing object shall be invalid. If the above circumstances occur when multiple new shares are issued on the same day, all the placing objects are invalid. If different placing objects share bank accounts, if the subscription funds are insufficient, the new shares allocated to the placing objects sharing bank accounts will be invalid. Offline investors are allocated multiple new shares on the same day. Please pay for each new share separately.
After winning the subscription of new shares, online investors shall fulfill the obligation of capital settlement in accordance with the announcement on the results of online winning the initial public offering of shares and listing on the gem of Chengda Pharmaceutical Co., Ltd., so as to ensure that their capital account will eventually have sufficient new share subscription funds on January 12 (T + 2) 2022, and the insufficient part shall be deemed as abandoning the subscription, The resulting consequences and relevant legal liabilities shall be borne by the investors themselves. The investor’s fund transfer shall comply with the relevant provisions of the securities company where the investor is located.
The shares abandoned by offline and online investors shall be underwritten by the sponsor (lead underwriter).
2. Among the shares issued this time, the shares issued online have no circulation restrictions and restricted sales period arrangements, and can be circulated from the date of listing of the shares issued this time on the Shenzhen Stock Exchange.
The offline issuance part adopts the proportional sales restriction method, and the offline investors shall promise that the sales restriction period of 10% (rounded up) of the number of shares allocated to them is 6 months from the date of the issuer’s initial public offering and listing. That is, among the shares allocated to each placing object, 90% of the shares are sold indefinitely and can be circulated from the date when the issued shares are listed and traded on the Shenzhen Stock Exchange; The sales restriction period of 10% of the shares is 6 months, which shall be calculated from the date of listing and trading of the issued shares on the Shenzhen Stock Exchange.
When offline investors participate in the preliminary inquiry and quotation and offline subscription, they do not need to fill in the lock-in period arrangement for the placement objects under their management. Once the quotation is made, it is deemed to accept the offline lock-in period arrangement disclosed in this announcement.
In the strategic placement part, the senior management and core employees of the issuer participate in the special asset management plan established by the strategic placement, and the restricted sale period of shares allocated is 12 months, which shall be calculated from the date of listing and trading of the issued shares on the Shenzhen Stock Exchange.
3. When the total number of shares paid and subscribed by offline and online investors is less than 70% of the number of public offerings after deducting the final strategic placement, the issuer and the sponsor (lead underwriter) will suspend the issuance of new shares and disclose the reasons for the suspension and subsequent arrangements.
4. If the offline investors who provide effective quotation fail to participate in the subscription or do not fully apply for the subscription, and the offline investors who obtain the preliminary placement fail to pay the subscription amount in time and in full, they will be deemed as breach of contract and shall bear the liability for breach of contract. The recommendation institution (lead underwriter) shall report the breach to the China Securities Association for the record.
If the online investor fails to make full payment after winning the lottery for 3 times in a row within 12 months, it shall not participate in the online subscription of new shares, depositary receipts, convertible corporate bonds and exchangeable corporate bonds within 6 months (calculated as 180 natural days, including the next day) from the next day of the settlement participant’s latest declaration of abandonment of subscription. 1、 Online subscription
According to the data provided by Shenzhen Stock Exchange, the sponsor (lead underwriter) has made statistics on the subscription of this online offering. The number of effective subscription accounts of this online pricing offering is 12444068, the number of effective subscription shares is 63207124000, the total number of allotments is 126414248, the starting number is 00000000000 1, and the ending number is 000126414248.
2、 Implementation of callback mechanism, issuance structure and success rate of online issuance
According to the callback mechanism announced in the announcement of Chengda Pharmaceutical Co., Ltd. initial public offering and listing on the gem, the issuer and the sponsor (lead underwriter) decided to start the callback mechanism because the initial effective online subscription multiple was 10254.23816 times, higher than 100 times, After deducting the final strategic placement, 20% of the number of publicly issued shares (rounded up to an integral multiple of 500 shares, i.e. 4653500 shares) will be transferred back online from offline. After the call back, the final number of offline shares issued was 124485700, accounting for 53.51% of the number issued after deducting the final strategic placement; The final number of shares issued online was 10.8175 million, accounting for 46.49% of the number issued after deducting the final strategic placement. After the call back, the winning rate of this online issuance is 0.0171143683%, and the effective subscription multiple is 5843.04359 times.
3、 Online lottery
The issuer and the sponsor (lead underwriter) will conduct lottery at Room 308, Shenye center, No. 5045, Shennan East Road, Luohu District, Shenzhen on the morning of January 11, 2022 (T + 1), and will publish the online lottery results on China Securities News, Shanghai Securities News, securities times and securities daily on January 12, 2022 (T + 2).
Issuer: sponsor (lead underwriter) of Chengda Pharmaceutical Co., Ltd.: Everbright Securities Company Limited(601788) January 11, 2022 (this page has no text, which is the seal page of the announcement on online subscription and winning rate of Chengda Pharmaceutical Co., Ltd. for initial public offering and listing on GEM)
The initial public announcement of Chengda Pharmaceutical Co., Ltd. on the Internet (no signature page of the issuer of Chengda Pharmaceutical Co., Ltd.)
Sponsor (lead underwriter): Everbright Securities Company Limited(601788) mm / DD / yy
